- Home
- XNDU vs ERAS Comparison
XNDU vs ERAS Comparison
Compare XNDU & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XNDU | ERAS |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.0B |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XNDU | ERAS |
|---|---|---|
| Price | $10.27 | $19.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $44.00 | $14.25 |
| AVG Volume (30 Days) | 981.0K | ★ 2.9M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.97 | $1.33 |
| 52 Week High | $42.44 | $24.28 |
Technical Indicators
Market Signals| Indicator | XNDU | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 44.00 |
| Support Level | $9.54 | $14.00 |
| Resistance Level | $11.64 | $18.20 |
| Average True Range (ATR) | 0.52 | 0.95 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 33.05 | 17.09 |
Price Performance
Historical ComparisonAbout XNDU Xanadu Quantum Technologies Limited Class B Subordinate Voting Shares
Xanadu Quantum Technologies Ltd specializes in designing photonic devices and the platforms around them, including the experimentation and development of quantum computers available on the cloud with supporting software, along with quantum simulators and other related products and offerings. Its products include: Aurora, PennyLane, Catalyst, Lightning, Catalyst and PennyLane Codebook. The company operates in industries such as automotive, aerospace, energy, materials, and semiconductor sectors.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.